Efficacy of Dashamoola Rasayana in mild to moderate stable Chronic Obstructive Pulmonary Disease against Conventional Modern Medications - A Comparative Randamised Clinical Trial.

This randomized, single blind, multicenter trial aims tocompare the efficacy of Dashmool Rasayan 3 grams, four times daily for 30days with conventional modern medications (inhaled bronchodilators,antimuscarinics, bita adrenergic agonists, and inhaled corticosteroids  inpatients with mild to moderate COPD. The primary outcome is the annual declinein lung function FEV1 over one year, indicating the progression of airflowobstruction. Secondary outcomes include the frequency of COPD exacerbations flare-upsrequiring treatment assessed over 45 days, changes in respiratory symptomssuch as shortness of breath, cough, and wheezing evaluated at 30 days, andchanges in depression levels as measured by the Beck Depression Inventory BDI score at 4 weeks. In COPD patients, mean baseline BDI scores typically rangebetween 14 and 20, indicating mild to moderate depression.